AMES | Jotup

University of Kentucky Study Finds 11 Bushel Higher Corn Yield with Pivot Bio Microbial Nitrogen

Retrieved on:

수요일, 3월 6, 2024

Natural Resources, AMES, North Carolina State University, Food, Farmer, Biomass, Seed, University, Environment, Nitrogen, Fertilizer

AMES, Iowa, March 6, 2024 /PRNewswire/ -- The University of Kentucky Martin-Gatton College of Agriculture, Food and Environment, a leading land-grant institution, recently found that replacing 40 pounds of synthetic nitrogen with Pivot Bio PROVEN® 40 can increase corn yields while reducing reliance on synthetic fertilizer. This study is part of over 400 university-led and on-farm trials conducted in 2023, one of the most significant research endeavors on microbial nitrogen to date.

Key Points:

This study is part of over 400 university-led and on-farm trials conducted in 2023, one of the most significant research endeavors on microbial nitrogen to date.
Higher yields suggest that applying microbial nitrogen in furrow can help bridge the nitrogen gap that can occur in fields with cover crop rotations.
Preston employs both no-till and cover crop practices in addition to Pivot Bio's microbial nitrogen.
Corn yields were similar across both nitrogen fertilizer rates; however, PROVEN 40 applied in furrow increased corn yields across both nitrogen rates.

Trace Genomics Raises Oversubscribed $10.5 Million Series B, Expanding Reach of Pioneering DNA Soil Intelligence Platform

Retrieved on:

화요일, 2월 20, 2024

Investment, Soil, AMES, AI, Intelligence, Research, Marketing, Farmer, Growth, Health, Series, Risk assessment, Big data, Agriculture, Farm, Machine learning, NUE, Genomics, DNA

AMES, Iowa, Feb. 20, 2024 /PRNewswire/ -- Trace Genomics (Trace), the industry leader in DNA-based soil intelligence, today announced its successful Series B funding round at $10.5 million led by existing investors S2G Ventures and Ajax Strategies, as well as new investor Rabo Ventures. The round exceeded expectations and demonstrated strong investor confidence in Trace's trajectory and growth strategy. With this additional funding, Trace plans to expand its commercial growth, making its offerings available to more farmers and agronomists.

Key Points:

With this additional funding, Trace plans to expand its commercial growth, making its offerings available to more farmers and agronomists.
Poornima Parameswaran, CEO and Co-founder of Trace, stated, "The Series B funding represents a pivotal milestone for Trace, positioning us to accelerate our reach with cutting-edge soil DNA intelligence solutions, and advancing sustainable agriculture with a focus on farmer profitability.
Trace Genomics, a leader in soil health innovation, has developed a groundbreaking way to understand what's happening beneath the surface of our farms.
By examining the DNA of organisms in soil, farmers can get an individualized and detailed picture of soil health.

POET and Summit Carbon Solutions Announce Carbon Capture Partnership

Retrieved on:

월요일, 1월 29, 2024

Carbon, CO2, Farmer, AMES, Biofuel, Summit, Partnership, Agriculture, POET, Transport, AG, Plant, Renewable energy

AMES AND SIOUX FALLS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- In a major step forward for the future of agriculture and biofuels, POET and Summit Carbon Solutions (Summit) announced a groundbreaking partnership connecting the world’s largest biofuel producer with the world’s largest carbon capture and storage project.

Key Points:

AMES AND SIOUX FALLS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- In a major step forward for the future of agriculture and biofuels, POET and Summit Carbon Solutions (Summit) announced a groundbreaking partnership connecting the world’s largest biofuel producer with the world’s largest carbon capture and storage project.
The partnership strategically expands the carbon opportunity across the Midwest by incorporating POET’s 12 facilities in Iowa and five facilities in South Dakota into the Summit project.
“POET is excited to partner with Summit Carbon Solutions on this historic project,” said Jeff Broin, POET Founder and CEO.
“As the world seeks low-carbon energy solutions, carbon capture ensures that ag-based biofuels will remain competitive for decades to come.

CES 2024 Netherlands Tech Pavilion Merges Tech and Nature for a VR Glimpse at a Sustainable Future

Retrieved on:

수요일, 1월 10, 2024

Cloud, Photonics, Research, Documentation, Medicine, Cancer, Computer, Carbon, 3D, Printing, Psychology, Virtual reality, VR, PUF, Pulse, Pollution, QSR, Ink, Bev, BIM, Kingdom, Heart, AMES, Sleep, SAN, Garden, Athlete, Physical, Behavior, Environment, Optimism, Cosmetics, AAL, Human, Safety, Marketing, Education, Hope, Congestion, Infrared, Health, Female, Software as a service, Pharmacist, AI, Nanotechnology, COPD, Tree, Glaucoma, CES, Plant, FMCW, ROI, Lidar, Speech, Patient, Music, University, Ecosystem, Interview, Diabetic retinopathy, Climate, Nature, AMR, Fast-food restaurant, Internet of things, Huber loss, Video game

"My role as a creative innovator is to inspire hope and optimism through my visual storytelling," said Tse. "When an environment is healthy, trees and plants will send energy and resources to plants that are hurting. There is a beautiful interdependence that exists in nature. When tech is created to help others, it's that same spirit of benevolence and community. 'Sustainable Garden' is meant to express that tech and nature can work together to forge a better future -- not just for humans, but the Earth and all living things."

Key Points:

The NL Tech Pavilion theme for CES 2024 is "Let's Innovate Sustainable Solutions," and the CES 2024 delegation features 12 CES 2024 Innovation Award winners.
'Sustainable Garden' is meant to express that tech and nature can work together to forge a better future -- not just for humans, but the Earth and all living things."
(Startup and CES 2024 Innovation Award Honoree )
Sevvy : Technology that enables healthy, sustainable and fast cooking and baking.
(Startup)
Interested media and analysts who want to schedule an interview with companies in the NL Tech Pavilion during CES 2024, please contact [email protected] .

GMS Reports Second Quarter Fiscal 2024 Results

Retrieved on:

목요일, 12월 7, 2023

GMS Inc. (NYSE: GMS), a leading North American specialty building products distributor, today reported financial results for the fiscal second quarter ended October 31, 2023.

Key Points:

GMS Inc. (NYSE: GMS), a leading North American specialty building products distributor, today reported financial results for the fiscal second quarter ended October 31, 2023.
Net debt leverage was 1.5 times as of the end of the quarter, down from 1.6 times at the end of the second quarter of fiscal 2023.
For the second quarter of fiscal 2024, cash provided by operating activities improved to $118.1 million, compared to cash provided by operating activities of $107.3 million in the prior year period.
GMS will host a conference call and webcast to discuss its results for the second quarter of fiscal 2024 ended October 31, 2023 and other information related to its business at 8:30 a.m. Eastern Time on Thursday, December 7, 2023.

Griffon Corporation Announces Annual and Fourth Quarter Results

Retrieved on:

수요일, 11월 15, 2023

Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today reported results for the fiscal year and fourth quarter ended September 30, 2023.

Key Points:

Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) today reported results for the fiscal year and fourth quarter ended September 30, 2023.
Revenue for the fourth quarter totaled $641 million, decreasing 10% from $709 million in the prior year quarter.
Adjusted EBITDA from continuing operations for the fourth quarter totaled $121.3 million, a 3% decrease from the prior year quarter of $124.8 million.
"We are pleased with Griffon’s results for the fourth quarter and fiscal year.

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Retrieved on:

월요일, 12월 18, 2023

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.

Key Points:

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
"The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
"FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."

NodeKit Raises a $1.2M Pre-Seed Round led by Borderless Capital to Build a Shared Sequencer L1

Retrieved on:

수요일, 12월 13, 2023

AMES, SEQ, Midwestern United States, Ageing, Ecosystem, University, L1, Doctor of Philosophy, Failure, Structure validation, Partnership, Asset management, Cryptocurrency, L2

AMES, Iowa, Dec. 13, 2023 /PRNewswire/ -- NodeKit, the team developing SEQ, a shared sequencer L1, has raised $1.2M in a pre-seed round. The round was led by Borderless Capital with participation from Avalanche's Blizzard Fund, Polygon Ventures, Wormhole Cross-Chain Ecosystem Fund, and many angels (including key angel investors such as Avail's Anurag Arjun and BENQI's @hn_avax). The team is using the funding to help decentralize the next generation of rollups powered by SEQ.

Key Points:

NodeKit's SEQ is a shared sequencer L1 designed to give a wide range of rollups more robustness, performance, uptime, and interoperability.
AMES, Iowa, Dec. 13, 2023 /PRNewswire/ -- NodeKit , the team developing SEQ, a shared sequencer L1, has raised $1.2M in a pre-seed round.
"Rollups desire a cost-effective, lightning-fast, decentralized sequencer to improve the quality of their users' experience.
Through SEQ, NodeKit introduces atomic composability and shared sequencing to the leading protocols bringing economic efficiency and true decentralization for cross-chain modularity."

GlobalVetLink Announces Integration with The Jockey Club InCompass Solutions

Retrieved on:

월요일, 11월 27, 2023

Organization, EIA, Jockey Club, Patient, Equine infectious anemia, Movement, Health, Veterinarian, Partnership, Horse, Veterinary medicine, AMES

AMES, Iowa, Nov. 27, 2023 /PRNewswire/ -- GlobalVetLink and The Jockey Club InCompass Solutions have partnered to streamline the creation of equine health and movement certificates for veterinarians. This new integration will enable veterinarians using the GlobalVetLink Compliance Assistant Platform to import horse information from InCompass through the horse's microchip number, speeding up the process of creating Equine Infectious Anemia (EIA) tests.

Key Points:

AMES, Iowa, Nov. 27, 2023 /PRNewswire/ -- GlobalVetLink and The Jockey Club InCompass Solutions have partnered to streamline the creation of equine health and movement certificates for veterinarians.
This new integration will enable veterinarians using the GlobalVetLink Compliance Assistant Platform to import horse information from InCompass through the horse's microchip number, speeding up the process of creating Equine Infectious Anemia (EIA) tests.
"InCompass' technology solutions help organizations achieve operational efficiencies, reduce costs, and increase revenue," said Chris Dobbins, senior vice president of InCompass.
Through the integration with InCompass, veterinarians can easily import a horse's information, including name, date of birth, breed, gender, and more, by locating the horse's record through a microchip search of The Jockey Club Registry.

GlobalVetLink Announces New GVL Pet TravelPass Feature for Streamlining EU Transit Certificate Creation

Retrieved on:

목요일, 11월 16, 2023

Pet, Movement, Health, Veterinarian, Customer support, Travel, Medical device, AMES

AMES, Iowa, Nov. 16, 2023 /PRNewswire/ -- GlobalVetLink is pleased to announce that its Compliance Assistant Platform now includes EU Transit Certificates, further simplifying the international pet travel process for veterinarians and practice staff. An EU Transit Certificate is required for any pet traveling through an EU country before arriving at their destination. This new feature of the GVL Pet TravelPass will guide veterinarians through creating an EU Transit Pet TravelPass after completing the Pet TravelPass for the final destination.

Key Points:

The GVL Pet TravelPass now assists veterinarians in creating the required EU Transit Certificate for pets transiting through an EU country during their overseas travel.
An EU Transit Certificate is required for any pet traveling through an EU country before arriving at their destination.
This new feature of the GVL Pet TravelPass will guide veterinarians through creating an EU Transit Pet TravelPass after completing the Pet TravelPass for the final destination.
GlobalVetLink customers with questions about the EU Transit Pet TravelPass feature can chat with the Customer Support team when logged into their GlobalVetLink account.